BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Files An 8-K Submission of Matters to a Vote of Security Holders

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

Story continues below

On December7, 2017, BioDelivery Sciences International, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the “Annual Meeting”). The number of shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) entitled to vote at the Annual Meeting was 55,883,436. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 45,789,273, thus establishing a quorum for the Annual Meeting. All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved and the director nominees were elected.

The following is a tabulation of the voting on the proposals presented at the Annual Meeting:

Proposal 1: To elect Frank E. O’Donnell, Jr. and William Mark Watson as ClassIII directors, each to serve for a three-year term that expires at the 2020 annual meeting of stockholders or until his successor is elected and qualified or until his earlier resignation or removal.

Nominee

SharesVotedFor SharesAbstaining BrokerNon-Votes

Frank E. O’Donnell, Jr.

21,107,769 4,322,936 20,358,568

William Mark Watson

23,934,262 1,496,443 20,358,568

Proposal 2: To ratify the appointment by the Audit Committee of the Company’s Board of Directors of Cherry Bekaert LLP as the Company’s registered public accounting firm for the fiscal year ending December31, 2017.

Shares Voted For

SharesAgainst

SharesAbstaining

BrokerNon-Votes

44,572,425

1,052,771 164,077

Proposal 3: To approve an amendment to the Company’s 2011 Equity Incentive Plan (the “Plan”) to, among other matters, increase the number of shares of Common Stock authorized for issuance under the Plan from 11,050,000 to 18,150,000. The form of amendment to the Plan was attached to the Company Notice of Annual Meeting, filed with Securities and Exchange Commission on November1, 2017.

Shares Voted For

SharesAgainst

SharesAbstaining

BrokerNon-Votes

22,364,981

2,961,422 104,302 20,358,568


About BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

An ad to help with our costs